Paper

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety Up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA ‐2 Trial

Arthritis & Rheumatology · 2026 · Philip J Mease, Vinod Chandran, April W Armstrong et al.